• A collaborative partnership was signed between the Center for Cellular & Molecular Biology and Aganitha, a global biopharmaceutical company.

• The partnership aims to use Aganitha's generative Al solutions to turn findings from the highly regarded research labs of CCMB into medicinal prospects, for example, predicting, testing, and optimizing antimalarial drugs.

• The Memorandum of Understanding (MoU) initially focuses on areas like , small molecule design, antibody engineering, and nanobody engineering for addressing malaria, tuberculosis, and neurological disorders.

• Dr. Raghunand Tirumalai highlighted the collaboration between CCMB and Aganitha in discovering small molecule inhibitors targeting essential proteins of Mycobacterium tuberculosis.

• Dr. Janesh Kumar emphasized the partnership's focus on developing nanobody binders for GluD1 neurotransmitter receptors, aiming to create new therapeutic options for neurological disorders such as Alzheimer's and epilepsy. 

• Prasad Chodavarapu noted this academia-industry collaboration's potential to address significant human health challenges.

Click here to read more.